Search by each research programme’s Therapeutic Application, including:

​

• FMT(Fecal Transplant): this approach involves the transfer of more or less processed fecal microbiome material from a healthy donor to a diseased individual.

• Defined Consortia: based on treating the patient with a consortium of several microbial species. Whereas some of these products have emerged from further processing and refinement of FMT, some others have been designed rationally attending at ecological properties, metabolic capacities or other features.

• Single species (strain): a single type of microorganism is administered to elicit the beneficial effect.

• Phages and viruses: using bacteriophages to kill bacteria and/or modulate the composition or activity of the microbiome, or mining for human viruses to find novel tools for human gene therapy (although the gene therapies themselves would be excluded from the scope of LBPs). Some viruses are native and others are engineered.

• GMOs( Genetically-Modified Organisms): engineering microbes to turn them into long-term drug delivery systems, or to expand or potentiate their metabolic activity.

• Molecules from the microbiome (also called postbiotics): Molecules (small molecules but also some biologics) originally mined from the microbiome and employed as therapeutic actives, with or without prior modification.

• Molecules for the microbiome: external chemicals (mostly small molecules, but also some biologics such as monoclonal antibodies) employed to therapeutically alter microbial activity and/or composition in the microbiome.

• Diagnostics, companion diagnostics and disease-monitoring technologies: microbial signatures and biomarkers have been linked with the risk of developing a disease or with its prognosis.